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Background: The quality and viability of mastectomy flaps remain a central challenge in reconstructive surgery,
particularly for immediate breast reconstruction. Insufficient perfusion in tissue flaps is a leading cause of early
complications following reconstructive procedures, and clinical judgment alone is not completely reliable for the
assessment of flap viability. Accurate and reliable intraoperative methods for assessment of tissue perfusion are
needed to help surgeons identify tissue at risk for ischemia and necrosis, thereby allowing for maneuvers to
improve tissue flap viability.
Methods: This study evaluates the use of intraoperative laser angiography using the SPY System (LifeCell Corp.,
Branchburg, NJ) for the assessment of perfusion in mastectomy flaps for immediate breast reconstruction. The SPY
System uses the contrast agent indocyanine green, which has an excellent safety profile and pharmacokinetics that
allow for repeat evaluations during the same surgical procedure. In recent work, the SPY System has demonstrated
high sensitivity and specificity for detection of tissues at risk for ischemia and necrosis during reconstructive
surgery. Using a retrospective, chart-review design, the authors compared consecutive cases of immediate breast
reconstruction using a prosthesis, before and after implementation of the SPY System.
Results: Ninety-one subjects were included in the analysis: 52 prior to SPY (Pre-SPY) and 39 after implementation of
SPY (Post-SPY). Baseline characteristics were similar between the groups. Both groups had high rates of
comorbidities, chemotherapy, and radiation therapy. The rate of postoperative complications was two-fold higher in
the Pre-SPY group compared to the Post-SPY group (36.5% vs. 17.9%); this difference was of borderline significance
(P = 0.0631). However, mean number of repeat visits to the OR per patient was significantly higher in the Pre-SPY
group (1.21 ± 1.47 vs. 0.41 ± 0.71; P = 0.0023). Of the seven patients with complications in the Post-SPY group, five
were identified by SPY as having poor flap perfusion; none were identified by clinical judgment alone.
Conclusions: This study suggests that the SPY System can contribute to reduced ischemia-related complications in
a population of women undergoing immediate breast reconstruction following mastectomy for breast cancer.* Correspondence: mo_sood@yahoo.com
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Approximately 40% of women who undergo mastectomy
for breast cancer will elect to have breast reconstruction
[1]. The optimal approach to postmastectomy breast re-
construction continues to evolve. Patient-, surgeon-, and
disease-related factors often influence the timing and
type of reconstruction selected. For appropriate patients,
U.S. practice has evolved to include immediate recon-
struction with one-stage, direct-to-implant procedures or
two-stage procedures with insertion of tissue expanders
(TE) followed by replacement with permanent implant.
Immediate reconstructive procedures have been made
more feasible through surgical approaches that preserve
the native skin envelope, including skin-sparing and
nipple-sparing mastectomy. Key issues in immediate re-
constructive procedures include coverage of the implant,
the use of appropriate TE, and the quality and viability
of tissue flaps.
In direct-to-implant procedures, local tissues and/or
reinforcing prostheses must be employed to provide ad-
equate coverage of the implant [2]. Recently, the use of
human acellular dermal matrix (HADM; AlloDerm
[LifeCell Corp., Branchburg, NJ]) has gained favor for
use in both direct-to-implant and TE breast reconstruc-
tions [3-7]. Characteristics of HADM that support its
use in this setting include pliability, strength, and the
promotion of cellular repopulation and revasculariza-
tion, which may increase its ability to resist or overcome
infection [8-10].
The quality and viability of mastectomy flaps is a cen-
tral challenge in reconstructive surgery. For immediate
reconstructive procedures, the flaps must be of sufficient
size to cover the TE or implant and must maintain ad-
equate blood flow to prevent necrosis or other complica-
tions. Indeed, a leading cause of early complications
following reconstructive procedures is insufficient per-
fusion in tissue flaps [11-14]. Furthermore, in the
postmastectomy setting, chemotherapy, radiation ther-
apy, and other variables are known to increase the risk
for impaired wound healing and other complications
[15,16]. The management of complications, particularly
those requiring return to the OR, is a major cost driver
for breast reconstructive procedures [17,18], for both the
patient and the hospital.
For these reasons, surgeons have evaluated and em-
ployed a number of methods to assess tissue perfusion in
the intraoperative setting. An ideal technique would allow
for accurate identification of perforating vessels and their
perfusion zones, assessment of tissue perfusion, and iden-
tification of tissue at risk for necrosis. Clinical judgment is
the most widely used method for evaluating blood supply
and tissue viability [19]. However, evidence suggests that
clinical assessment alone is not completely reliable for as-
sessment of tissue perfusion [20,21].Technologies evaluated for assessment of tissue per-
fusion in the intraoperative setting include hand-held
Doppler, laser Doppler flowmetry, and fluorescein angiog-
raphy [22-26]. Each of these methods suffers from
significant limitations. Evidence suggests that Doppler
ultrasound is operator-dependent and provides limited ac-
curacy for flap design [22-27]. Laser Doppler is cumber-
some, may underestimate flap survival, and may have
poor ability to detect perforators [23,24]. Fluorescein is
limited by the long half life of the contrast medium, which
prevents re-evaluation during the intraoperative period,
and the potential for false-positive findings [25,28,29].
In recent years, some surgeons have adopted indocyanine
green (ICG) angiography, using the SPY intraoperative
perfusion assessment system (LifeCell Corp., Branchburg,
NJ), for assessment of tissue perfusion in mastectomy
flaps [13,30-32]. The fluorescence agent ICG has a short
half life, binds strongly to plasma proteins, and has an ex-
cellent safety profile, allowing for rapid clearance from tis-
sues and the performance of repeat evaluations during the
same surgical procedure [33]. Recent work suggest that
the SPY system also provides greater accuracy compared
to fluorescein or clinical judgment for prediction of mast-
ectomy flap necrosis [34].
The current retrospective, chart-review study was
undertaken to evaluate the impact of the adoption of the
SPY system on complications following immediate TE-
or implant-based breast reconstruction with HADM fol-
lowing mastectomy.
Methods
The study was performed at a single institution in a
retrospective, chart-review design. All surgeries were
performed by the authors. The study compared consecu-
tive cases of immediate breast reconstruction using
prosthesis before (January 1, 2009 – April 1, 2011) and
after (April 1, 2011 – April 30, 2012) implementation of
the SPY intraoperative perfusion assessment system for
reconstructive procedures. This study was granted ex-
emption from IRB review based on its retrospective,
chart-review design.
Subjects were identified through analysis of hospital
records. Consecutive patients undergoing immediate
breast reconstruction with a prosthesis following mast-
ectomy for treatment of breast cancer were included.
Subjects treated with TE and/or implants were included.
Subjects treated with delayed procedures or flap-based
reconstructions were excluded. All breast reconstruc-
tions in this study were performed using HADM. Data
were collected for subject age, tumor stage, surgery, to-
bacco use, comorbidities, implant size, number of repeat
trips to OR, and complications.
All implant reconstructions were performed using a
standard sub-pectoral implant position. The pectoralis
Table 1 Baseline characteristics of subjects
Pre-SPY Post-SPY P-value*
N 52 39
Age, mean (SD) 52 (7.9) 51 (8.6) 0.5666
Any smoking, N (%) 13 (25.5)** 14 (35.9) 0.3550
Comorbidities present, total, N (%) 40 (78.4)** 24 (61.5) 0.1020
Diabetes, N (%) 3 (7.7%) 1.000
Obesity, N (%) 5 (9.6%) 2 (5.1%) 1.000
2 (3.8%)
Tumor status, N (%)
T1 21 (40.4) 10 (25.6) NS†
≥T2 26 (50.0) 24 (46.2)
N0 27 (51.9) 19 (48.7)
≥N1 21 (40.4) 15 (28.8)
M0 42 (80.8) 32 (82.1)
M1 5 (9.6) 2 (5.1)
DCIS 5 (9.6) 2 (5.1)
Other 1 (1.9) 3 (7.7)
Therapy
Any chemotherapy, N (%) 40 (76.9) 25 (64) NS‡
Any hormonal therapy, N (%) 29 (55.8) 18 (46.1)
Any radiation, N (%) 27 (51.9) 17 (43.6)
No therapy, N (%) 4 (7.7) 5 (12.8)
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ments. Once completed, the implant was soaked in anti-
biotic solution and placed into the pocket. For inferior
coverage, HADM was secured to the edge of the cut
pectoralis and the inframammary shelf. The wounds
were thoroughly irrigated and drains were placed into
the axilla and inferior aspect of the wound. Mastectomy
flaps were routinely closed in a layered fashion with
interrupted 3.0 polydioxanone deep dermal suture and
4.0 monocryl intradermal closure.
Once SPY became available at the authors’ institution,
the device was used in addition to clinical judgment to
assess perfusion in mastectomy flaps after the general
surgeon completed the mastectomy and prior to any re-
constructive procedures. Briefly, 3 cc ICG were adminis-
tered by IV push, followed by 10 cc normal saline flush.
Fluorescence images were captured using the digital
camera on the SPY System and archived for reference.
Areas of low fluorescence, indicating limited perfusion
in the flap, were noted, and maneuvers were performed
to improve perfusion according to surgeon judgment
and preference. These maneuvers included resection of
skin in potentially ischemic areas and/or reduction of
implant volume.
Analysis of the data was performed using chi square
and Fisher’s exact test for categorical variables and un-
paired two-tailed t-test for continuous variables.* Unpaired two-tailed t-test.
** Data missing for one subject.
† No significant interaction by group and tumor status: T1 vs. >T1, N0 vs. >N0,
or M0 vs. M1, Fisher’s exact test.
‡ No significant interaction by group and each therapy vs. absence of each
therapy, Fisher’s exact test.
DCIS: ductal carcinoma in situ.
NS: Not significant at P < 0.05.
Note: identified comorbidities included hypertension, diabetes, obesity,
asthma, hyperlipidemia, thyroid disease, gastroesophageal reflux disease,
osteoporosis, irritable bowel syndrome, thyroid disease, arthritis,
endometriosis, chronic bronchitis, sinusitis, hepatitis B, deep vein thrombosis,
rheumatic fever, lupus, obstructive sleep apnea, sickle cell disease, anxiety,
and depression.Results
A total of 95 consecutive subjects met the inclusion cri-
teria for this study, 54 prior to (Pre-SPY) and 41 after
implementation of SPY (Post-SPY). Two subjects in the
Pre-SPY group were excluded based on flap reconstruc-
tions; two subjects in the Post-SPY group were excluded,
one for flap reconstruction and one for delayed recon-
struction. Therefore, the final sample included 52 sub-
jects in the Pre-SPY group and 39 in the Post-SPY group.
There were 24 unilateral reconstructions and 28 bilateral
reconstructions, totaling 80 operated breasts. Demo-
graphic and baseline characteristics of the subjects are
listed in Table 1. There were no significant differences be-
tween groups in terms of age, presence of comorbidities,
history of smoking, tumor status, or cancer therapy
(chemotherapy, hormonal therapy, radiation therapy).
There were no significant differences between groups
with regard to reconstructive modality (Table 2). Similar
proportions of each group underwent bilateral (Pre-SPY,
53.8%; Post-SPY, 59%) and unilateral (Pre-SPY, 46.2%;
Post-SPY, 41.0%) breast reconstruction. There were no
significant differences between groups in the use of TE
or implants. Mean implant size was greater in the Post-
SPY group (mean 575.9 vs. 519.8 cc), but this difference
did not reach statistical significance (P = 0.074).The rate of complications was more than twice as high
in the Pre-SPY group compared to the Post-SPY group
(36.5% vs. 17.9%; Table 2); this finding approached but did
not reach statistical significance (P = 0.0631). The rate of
flap necrosis was 17% in the Pre-SPY group compared to
10% in the Post-SPY group (P = 0.383). Nineteeen (36.5%)
patients in the Pre-SPY group developed complications.
These complications included flap necrosis (9 patients),
capsular contraction (5 patients), cellulitis (2 patients), ex-
trusion of the TE (1 patient), displacement of the implants
(1 patient), and deflation of the TE (1 patient). Seven
(17.9%) patients in the Post-SPY group developed compli-
cations. Five of these patients were identified by SPY as
having poor flap perfusion (see Table 3); none were identi-
fied by clinical assessment alone. For the five patients in
this group identified by SPY as having poor perfusion,
Table 2 Surgical treatments and outcomes, by group
Pre-SPY Post-SPY P-value
Bilateral, N (%) 28 (53.8) 23 (59.0) 0.674†
Unilateral, N (%) 24 (46.2) 16 (41.0)
Implant, N (%) 49 (94.2)* 22 (56.4) 0.215†
Tissue expander, N (%) 22 (42.3)* 17 (43.6)
Implant size, mean cc (SD) 519.8 (164.7) 575.9 (140.5) 0.074**
Total complications, N (%) 19 (36.5) 7 (17.9) 0.0631†
Flap necrosis 9 (17.3) 4 (10.3)
Capsular contracture 5 (9.6) 0 (0.0)
Cellulitis 2 (3.8) 1 (2.6)
Hematoma 0 (0.0) 1 (2.6)
Extrusion of TE 1 (1.9) 0 (0.0)
Displacement of implant 1 (1.9) 0 (0.0)
Deflation of TE 1 (1.9) 0 (0.0)
Other 0 (0.0) 1 (2.6)‡
No. repeat OR visits, mean (SD) 1.21 (1.47) 0.41 (0.71) 0.0023**
*Includes multiple repeat procedures for individual patients.
**Unpaired t-test.
†Fisher’s exact test.
‡One incidental suture spitting noted during port placement.
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including debrediment of non-perfused tissue, deflation of
the tissue expander to improve blood flow, and the use of
transdermal nitroglycerin ointment to treat vasospasm.
Complications for these seven patients in the Post-SPY
group included necrosis of skin flaps and/or nipple (4 pa-
tients), hematoma (1 patient), cellulitis and seroma (1 pa-
tient), and incidental suture spitting noted during port
placement (1 patient). Five of these patients’ complications
(necrosis [n = 4] and cellulitis [n = 1]) could relate to poor
perfusion. The others (hematoma and suture spitting) are
unlikely to be related to perfusion.Table 3 Number of patients with complications, by
ischemia assessment method
Assessment method Patients with complications
SPY
Ischemia present, N (%) 5 (71.4)*
No ischemia detected, N (%) 2 (28.6)**
Clinical assessment
Ischemia present, N (%) 0 (0.0)
No ischemia detected, N (%) 7 (100)
Total patients with complications, N (%) 7 (100)
Note: percent of patients with complications by assessment method and
presence of ischemia/total number of patients with complications (N = 7).
* Complications in these patients included flap necrosis (n = 4) and suture
failure (n = 1).
** Complications in these patients included hematoma (n = 1) and cellulitis
and seroma (n = 1).Two additional analyses were performed based on the
potential relationship between complications and ische-
mia. The first compared the combined incidence of flap
necrosis and cellulitis between groups (Pre-SPY n = 11,
Post-SPY n = 5); this comparison was not statistically sig-
nificant (P = 0.407). Based on evidence that ischemia
could contribute to capsular contracture, the second
analysis compared the combined incidence of flap necro-
sis, cellulitis, and capsular contracture between groups
(Pre-SPY n = 16; Post-SPY n = 5); this difference was sta-
tistically significant (P = 0.0492).
In the Pre-SPY group, 32 patients (61.5%) required re-
turn visits to the OR (total of 63 visits); in the post-SPY
group, 11 patients (28.2%) required return visits to the
OR (total of 14 visits). Mean number of repeat visits to
the OR per patient was significantly higher in the Pre-
SPY group: 1.21 ± 1.47 vs. 0.36 ± 0.66 (95% confidence
interval 0.3477 – 1.3523; P = 0.0011). The most common
procedure performed on return to the OR in the Pre-
SPY group was revision to treat dehiscence or necrosis
(10 patients), followed by implant exchange (8 patients),
capsular contracture (5 patients), minor revisions (4 pa-
tients), and other procedures (1 patient). The most com-
mon procedures performed on return to the OR in the
Post-SPY group were implant exchange (4 patients) and
treatment of necrosis (4 patients); one patient each was
treated for cellulitis, hematoma, and suture spitting.
Following implementation of SPY, perfusion in the
mastectomy flaps was assessed both by SPY imaging and
clinical judgment (see Table 4). Rates of identification of
ischemia by clinical assessment and SPY were highly sig-
nificantly different (P < 0.0001). In the Post-SPY sample,
only one patient (2.6%) was determined by clinical as-
sessment to have poor perfusion in the mastectomy
flaps. Conversely, SPY imaging identified poor flap per-
fusion in 20 patients (51.3%), including the one patient
identified by clinical assessment. Most of these patients
(N = 18, 90%) were managed by resection of skin in the
affected area; implant volume was decreased in nine










SPY, N (%) 20 (51.3) 19 (48.7) 18 (90)† 9 (45)† <0.0001
Clinical judgment,
N (%)
1 (2.6) 38 (97.4) 1 (100)† 1 (100)†
* Management of ischemia in patients with “yes” answer, by method of assessment.
** Fisher’s exact test, presence of ischemia: SPY vs. clinical judgment.
† Management approach by percent of patients with ischemia (N = 20 SPY,
N = 1 clinical judgment).
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perfusion are illustrated in Figures 1 and 2.
Discussion
Optimizing outcomes of postmastectomy breast recon-
struction requires exploration of surgical techniques,
materials, and technologies designed to improve cos-
mesis, limit costs, and minimize complications. In par-
ticular, surgeons and patients will benefit from the
application of techniques that can identify ischemia in
tissue flaps, allowing surgeons the opportunity to per-
form operative revisions and prevent ischemia-related
complications. We believe this is one of the first studies
to compare outcomes before and after implementation
of SPY in postmastectomy patients treated with immedi-
ate breast reconstruction.
This retrospective study examined the use of the SPY
intraoperative perfusion assessment system for the
evaluation of tissue perfusion in mastectomy flaps in
consecutive patients undergoing immediate breast recon-
struction. The results demonstrate a two-fold reduction in
overall complication rate following the introduction of
SPY (36.5% to 17.3%). Although this difference did notFigure 1 Illustration of the use of the SPY System for evaluation of ti
fluorescence image (Panel A) shows large dark area of minimal fluorescen
pen can be seen tracing the outline of this region. Panel B is a colorized v
fluorescence (numbers in boxes); darker colors represent areas of lower fluo
C; areas of poor perfusion identified by SPY are noted in blue-pen outlines
tissue viability (including appearance of skin and presence of bleeding at ti
perfusion noted on SPY were left intact. The post-operative result (Panel D
of poor perfusion identified by SPY.achieve statistical significance (P = 0.0631), it strongly sug-
gests that the use of intraoperative methods to accurately
determine tissue perfusion as an augment to clinical judg-
ment can profoundly reduce the incidence of ischemia,
flap necrosis, and related complications. The impact of
these complications may also be evident in reduced pa-
tient quality of life and additional financial costs to the in-
dividual hospital and the overall healthcare system. These
potential impacts are bolstered by the significant differ-
ence between groups with regard to repeat OR visits (1.21
vs. 0.36; P = 0.0023). The lower rate of repeat OR visits in
the Post-SPY group could relate to reduced need for op-
erative treatment of complications in this group.
Previous studies of SPY in breast reconstruction have
reported a strong correlation between fluorescence pat-
tern on SPY and postoperative necrosis [11,30,31,35,36].
One recent, prospective study compared clinical judg-
ment, fluorescein, and SPY for evaluation of tissue perfu-
sion in 32 patients undergoing TE-implant reconstruction
[34]. In this study, SPY demonstrated a sensitivity of 90%
and specificity of 50% for prediction of necrosis. These
and other investigators have also undertaken analysis of
fluorescence values as determined by a SPY softwaressue perfusion in a mastectomy flap. The black-and-white
ce, reflecting poor perfusion, surrounding the incision; the surgeon’s
ersion of the same image, showing quantification of absolute
rescence signal. The incision prior to reconstruction is shown in Panel
superior and inferior to the incision. In this case, clinical judgment of
ssue edge) was favored over SPY findings, and the regions of poor
) shows necrosis superior to the incision, corresponding to the region
Figure 2 Use of SPY to identify areas of poor perfusion prior to reconstruction. The colorized SPY image of the left breast (Panel A) shows a
region of low fluorescence (dark blue), corresponding to the nipple-areola complex (NAC). Numbers reflect quantification of absolute fluorescence
values. Based on clinical judgment of tissue viability (including appearance of skin and presence of bleeding at tissue edge), the area identified by SPY
was not removed. Following reconstruction (Panel B), the NAC appears dusky inferior to the incision. Ultimately, the NAC region identified by SPY as
having poor perfusion developed necrosis (Panel C) and required return to the OR for debridement and removal of the NAC (Panel D).
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for ischemic versus non-ischemic tissue [34,37]. Phillips
et al. identified a threshold of 3.7 absolute perfusion units,
below which SPY had a sensitivity of 90% and specificity
of 100% for prediction of necrosis [34]. Validation of such
findings could provide surgeons with objective determi-
nants of tissue perfusion and the accurate prediction of
tissue necrosis using SPY.
Reported complication rates following immediate breast
reconstruction range from ~4% to ~60% [2,16,38-41]. The
overall complication rates in the current study fit within
previously reported ranges. The relatively high rate of
complications described in this and other studies of breast
reconstruction may relate to several factors. Examination
of breast tissue suggests that the breast harbors multiple
endogenous bacteria that may contribute to postoperative
infection, and it has been proposed that the breast should
be considered a clean-contaminated surgical site [42].
Other factors prevalent in the current and previous stu-
dies include a high rate of comorbidities and the use of
cancer therapies, such as chemotherapy and radiation
therapy, each of which has been shown to increase the risk
for postoperative complications following breast recon-
struction [2,43-45]. Independent risk factors for surgical
site infection (SSI) that have been identified following TE
breast reconstruction include larger breast size, previousirradiation, repeated implants, and delayed reconstruction
[2,46]. In one study of immediate breast reconstruction,
irradiation increased risk for complications four fold
[2]. Patient characteristics associated with increased risk
for postoperative complications include smoking, obesity,
and diabetes, among others [47-49].
In the current study, 78.4% and 61.5% of subjects in the
Pre- and Post-SPY groups, respectively, had comorbidities
at the time of surgery, including obesity, smoking, and
diabetes. Rates of chemotherapy (76.9% Pre-SPY, 64%
Post-SPY) and radiation therapy (51.9% Pre-SPY, 43.6%
Post-SPY) were also high in both groups. Therefore, a high
rate of complications could be expected based on these
patient- and treatment-related factors. The expected high
rate of complications highlights the potential benefits and
economic value of augmenting clinical judgment with the
use of SPY, which halved the complication rate in this
challenging patient population.
The choice of immediate versus delayed reconstruction
may also influence outcomes [16,50]. Immediate recon-
struction has the potential to reduce number of ope-
rations, costs, and the period of disfigurement for
appropriate patients [51,52]. However, some research sug-
gests higher complication rates associated with immediate
reconstruction. One comparison of immediate and de-
layed breast reconstructions found a significantly higher
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TE compared to delayed reconstruction (P = 0.008). Inter-
estingly, capsular contracture was significantly more com-
mon following immediate (40.4%) compared to delayed
reconstruction (17%; P < 0.001) [50].
Several complications, in addition to flap necrosis,
may be associated with poor perfusion. These potential
complications of ischemia, including infection (eg, cellu-
litis), poor wound healing, anastomotic thrombosis, and
fat necrosis, have been described in the surgical litera-
ture [53-57]. Some evidence suggests that seemingly un-
related complications, such as capsular contracture, may
also be influenced by ischemia. In the current study,
capsular contracture was identified as a complication in
9.6% of subjects in the Pre-SPY group and 0% of the
Post-SPY group. Identified risk factors for capsular con-
tracture include clinical or subclinical infection, and bac-
terial colonization of breast implants and the TE pocket
has been reported [58-61]. Therefore, it is possible that
the use of SPY could contribute to a reduction in cap-
sular contracture rates by allowing the surgeon to
optimize tissue perfusion and minimize ischemia and
necrosis in the flap. It is also possible that capsular con-
tracture presents over a longer time frame, and the
shorter follow up in the Post-SPY group has yet to en-
compass these events. One interesting development is
the emergence of data suggesting that HADM can miti-
gate capsular contracture [2,6]. It is possible that the use
of HADM in the current study contributed to a rela-
tively low incidence of capsular contracture.
Technical considerations
It became apparent that there was a learning curve associ-
ated with the use of SPY. Initially, the authors were reluc-
tant to rely on SPY findings when they conflicted with
clinical assessment. After evaluation of initial results using
SPY, treating surgeons gave greater importance to SPY
findings. This learning period lasted approximately three
months (~April 1 – July 1, 2011). A total of 7 patients (2
with complications) in the Post-SPY group underwent ini-
tial operation during this learning period. Removal of
these cases from the Post-SPY group identified a total of
32 patients, 5 (15.6%) of whom had complications.
Comparison of this post-learning period SPY group to
the Pre-SPY group demonstrated a significant difference
in complication rates (36.5% vs. 15.6%; P = 0.0484).
The impact of this learning period is exemplified by
specific patients in the Post-SPY group (see Figures 1
and 2). For example, one case performed soon after the
introduction of SPY (June 17, 2011) was determined by
clinical assessment to have adequate perfusion in the
mastectomy flaps. However, SPY identified regions of
low fluorescence, indicating poor tissue perfusion. In this
case, the authors relied on clinical assessment over theSPY findings, and no revisions were made. The patient
subsequently developed skin flap necrosis and TE extru-
sion one month later. This type of post-operative com-
plication also results in increased costs to the hospital
and reduced quality of life for the patient.
Cost considerations
Postoperative complications can have a profound impact
on total costs of care. One analysis of 949 women under-
going breast surgery reported that patients with SSI had
crude median costs of $16,882, compared to $6,123 for
uninfected patients [57]. On multivariate analysis, the
cost attributable to SSI for postmastectomy breast re-
construction procedures was $4,091. With an estimated
$14 billion spent annually in the U.S. on care for pa-
tients with breast cancer, it is likely that even modest re-
ductions in complication rates following reconstructive
surgery could have substantial impact on the overall cost
to individuals, payers, and society [62].
Several groups have suggested that immediate recon-
struction may provide cost savings over delayed proce-
dures [52,60]. A systematic review study analyzed cost
data for the use of HADM in breast reconstruction and
found that direct-to-implant reconstructions with HADM
were associated with lower costs compared to two-stage,
non-HADM procedures [63].
Limitations
The main limitations of this study are its retrospective,
non-randomized design and small sample size. Future
studies would benefit from prospective data collection,
randomization of subjects, and sample size powered to
detect differences in rates of specific complications.
Conclusions
This study provides initial evidence of the effectiveness
of the SPY System in reducing ischemia-related compli-
cations in a population of women undergoing immediate
breast reconstruction following mastectomy for breast
cancer.
To our knowledge, this is one of the first reports to
compare complication rates before and after implementa-
tion of SPY in this patient population. These initial find-
ings must be replicated in larger, prospective studies to
provide surgeons with valuable guidance regarding the po-
tential of SPY to predict tissue necrosis in breast recon-
struction procedures and illustrate the potential costs
savings to hospitals and improved quality of life for breast
cancer patients undergoing reconstruction. Future out-
come analyses should also include financial analysis to de-
termine if improved intraoperative perfusion assessment
reduces total costs through the avoidance of complications
requiring additional care.
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